Free Trial

Dr. Reddy's Laboratories Q1 2025 Earnings Report

Dr. Reddy's Laboratories logo
$14.21 -0.09 (-0.63%)
(As of 01:52 PM ET)

Dr. Reddy's Laboratories EPS Results

Actual EPS
$0.20
Consensus EPS
$0.22
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Dr. Reddy's Laboratories Revenue Results

Actual Revenue
$919.80 million
Expected Revenue
$861.68 million
Beat/Miss
Beat by +$58.12 million
YoY Revenue Growth
N/A

Dr. Reddy's Laboratories Announcement Details

Quarter
Q1 2025
Time
N/A

Conference Call Resources

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Dr. Reddy's Laboratories Earnings Headlines

Dr. Reddy’s Boosts Workforce with Equity Allotment
What is Zacks Research's Estimate for RDY FY2025 Earnings?
One coin could soar when Trump’s elected …
Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”
Dr. Reddy's Launches Toripalimab For Nasopharyngeal Carcinoma In India
Dr. Reddy’s Fined in Germany for Registration Lapse
See More Dr. Reddy's Laboratories Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dr. Reddy's Laboratories? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dr. Reddy's Laboratories and other key companies, straight to your email.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

View Dr. Reddy's Laboratories Profile

More Earnings Resources from MarketBeat